These sales are trivial and routine, ignore them. The real risk for KPTI is the $400M shelf registration (200%+ dilution) and cash runway ending late Q3 2026. Watch for an equity offering or partnership announcement as the financing catalyst, not insider trading patterns.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $7.14entry
- T+1 · 6mo ago +4.62%α +5.27% · $7.47
- T+5 · 6mo ago +25.63%α +24.01% · $8.97
- T+20 · 5mo ago +27.45%α +25.87% · $9.10
- T+60 · 3mo ago −71.57%α −76.42% · $2.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Six KPTI insiders, including CEO Richard Paulson, sold shares on May 14 (the same day as Q1 earnings), totaling $35,000 in open-market sales. The dollar value is 0.02% of the $185M market cap, well below the 0.1% materiality floor. This is a routine cluster timed to a blackout-window opening, not an informed bearish signal. Separately, a director received a $0 grant of 15,508 shares on May 21 as non-cash compensation.
Key Financial Metrics
Key Facts
- Six insiders, including the CEO and CFO, sold shares on May 14 at $9.50, totaling $35,000.
- Sales represent 0.02% of $185M market cap, immaterial by all proportionality standards.
- Director Barry Greene received a 15,508-share $0 grant on May 21 (non-cash compensation).
- Sales occurred on earnings day (Q1 2026 results filed May 14), consistent with a blackout-window opening.
Financial Impact
Total insider sales of $35K, or ~0.02% of market cap; plus $0 non-cash grant
Risk Factors
- $400M shelf registration filed May 4 creates massive potential dilution (~200% of current market cap).
- Cash runway only extends into late Q3 2026, acute financing risk constrains the stock.
- Phase 3 SENTRY myelofibrosis trial missed a co-primary endpoint, creating pipeline uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KPTI-1779826082813 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers